-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Just into September, more than 10 injections (in terms of drug name + group) have passed or are deemed to have passed the consistency evaluation
.
According to the data of the Intranet, the current evaluation/deemed overrated injections have exceeded 1,000 (in terms of drug names + groups), involving 264 varieties
.
From the perspective of evaluated enterprises, the top 10 enterprises have rated 17 or more injections, and the head enterprises such as Yangtze River, Kelun and Qilu have performed well; From the perspective of evaluated varieties, 7 of the TOP10 varieties have a peak sales of more than 2 billion yuan in the terminals of public medical institutions in China, of which 6 have 20 or more rated enterprises; From the perspective of treatment categories, the injectables have been evaluated to focus on the five hundred billion markets
.
.
According to the data of the Intranet, the current evaluation/deemed overrated injections have exceeded 1,000 (in terms of drug names + groups), involving 264 varieties
.
From the perspective of evaluated enterprises, the top 10 enterprises have rated 17 or more injections, and the head enterprises such as Yangtze River, Kelun and Qilu have performed well; From the perspective of evaluated varieties, 7 of the TOP10 varieties have a peak sales of more than 2 billion yuan in the terminals of public medical institutions in China, of which 6 have 20 or more rated enterprises; From the perspective of treatment categories, the injectables have been evaluated to focus on the five hundred billion markets
.
Injections have been rated as TOP10 enterprises: Yangzijiang, Kelun, Qilu performance is eye-catching
More than 20 pharmaceutical companies have rated the number of injectable varieties of 10 or more, among the TOP10 enterprises, Yangzijiang ranked first with 50 evaluated varieties (12 as the first), Kelun Pharmaceutical ranked third with 43 overrated varieties (21 as the first), and Qilu Pharmaceutical ranked third
with 39 evaluated varieties (15 as the first).
with 39 evaluated varieties (15 as the first).
In addition, the number of rated varieties of China Biopharmaceuticals and Beite Pharmaceuticals has reached 30 or more, and the number of rated varieties of Hengrui Pharmaceutical, CSPC Pharmaceutical Group and Fu'an Pharmaceutical has reached 20 or more
.
.
Top 10 Injectables Rated (Group)
Source: MED2.
0 China Drug Review Database
0 China Drug Review Database
Yangzijiang Pharmaceutical's 50 overrated injections cover 11 therapeutic categories, focusing on systemic anti-infective drugs (10 varieties), nervous system drugs (8 varieties), anti-tumor and immunomodulators (8 varieties), musculoskeletal system (7 varieties) and other therapeutic fields; The first of the 12 injections / exclusive reviews, of which Sulgen Glucose Sodium Injection, Tedezolid Phosphate for Injection, etc.
are the first imitation (containing the first imitation of the dosage form).
are the first imitation (containing the first imitation of the dosage form).
Yangtze River Pharmaceutical has evaluated the injection
Note: With * for the first / exclusive review
Source: MED2.
0 China Drug Review Database
0 China Drug Review Database
The 43 overrated injections of Kelun Pharmaceuticals cover 8 therapeutic categories, focusing on the two therapeutic areas of hematological and hematopoietic system drugs (17 varieties) and systemic anti-infective drugs (11 varieties); The first of 21 injections / exclusive reviews, a number of enteral nutrition products won the first imitation (containing dosage form first imitation).
Kelun Pharmaceuticals has evaluated injections
Note: With * for the first / exclusive review
Source: MED2.
0 China Drug Review Database
0 China Drug Review Database
Qilu Pharmaceutical's 39 overrated injections cover 7 treatment categories, focusing on two major therapeutic fields: anti-tumor and immunomodulators (12 varieties) and systemic anti-infective drugs (12 varieties); The first of the 15 injections has been evaluated, of which aprepitant injection is the first imitation (containing the first imitation of the dosage form).
Qilu Pharmaceutical has evaluated the injection
Note: With * for the first / exclusive review
Source: MED2.
0 China Drug Review Database
0 China Drug Review Database
The number of rated enterprises TOP10 injections: siege of large varieties, 6 major varieties of hot
More than 20 injections have been evaluated by 10 or more companies, among the TOP10 injections, the number of ambroxol hydrochloride injections has reached 40, the number of parecoxib sodium for injection has exceeded 30, and the number of omeprazole sodium for injection, pantoprazole sodium for injection, ceftriaxone sodium for injection, and espalprazole sodium for injection have reached 20 or more
.
.
From the terminal sales of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions), the peak sales of omeprazole sodium for injection, pantoprazole sodium for injection, and ceftazidime for injection have exceeded 5 billion yuan
.
.
The number of rated enterprises TOP10 injections
Source: Intranet Database
Judging from the situation of collection and procurement, the number of injections that have been evaluated by 10 or more enterprises has been included in the national collection, and the sales scale of most injections has declined to varying degrees after being included in the collection, but there are also individual exceptions
.
.
Dexmedetomidine hydrochloride injection is 4 + 7 and expand the collection of varieties, Yangtze River with the advantage of exclusive evaluation, with a low reduction in the exclusive selection, after the selection of rapid release, driving the entire market rapid expansion; The concentrated solution for levetiracetam injection was included in the third batch of collection, and the volume of "barefoot" selected enterprises such as Hainan Puli Pharmaceutical, Hebei Renhe Yikang Pharmaceutical, chongqing Shenghuaxi Pharmaceutical co.
, Ltd.
drove the sales of the entire variety to increase
year by year.
, Ltd.
drove the sales of the entire variety to increase
year by year.
In recent years, the terminal sales of some collection injections in Public Medical Institutions in China (: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
Overrated injection treatment category TOP10: focus on 5 hundred billion markets
More than 1,000 overrated injections (in terms of drug name + group) cover 11 treatment categories, and the proportion of five major therapeutic areas of systemic anti-infective drugs, digestive and metabolic drugs, nervous system drugs, blood and hematopoietic system drugs, anti-tumor and immunomodulators accounts for more than 10%.
Overrated injection treatment category TOP10
According to data from the Intranet, the sales scale of the five treatment categories of systemic anti-infective drugs, digestive and metabolic drugs, nervous system drugs, blood and hematopoietic system drugs, anti-tumor and immunomodulators will exceed 100 billion yuan
in the terminals of China's public medical institutions in 2021.
in the terminals of China's public medical institutions in 2021.
In recent years, the proportion of injection sales in the terminal part of China's public medical institutions has been the proportion of injections
Source: Intranet China's public medical institution terminal competition pattern
From the distribution of dosage forms in the above 5 treatment categories, injections occupy a dominant position, of which injections account for more than 80% of drugs in the blood and hematopoietic system, which are mainly driven by the sales of human blood albumin, sodium chloride injection, glucose injection and other products; In addition, even under the influence of policies such as limiting the amount of import and limiting antibody, the proportion of injections in systemic anti-infective drugs is still increasing year by year, and it has approached 80%
in 2021.
in 2021.
Source: Intranet database, the official website of the State Food and Drug Administration, etc.
Note: Minenet "China's Public Medical Institutions Terminal Competition Pattern", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Statistics as of September 5, if there is any omission, welcome to correct!
Note: Minenet "China's Public Medical Institutions Terminal Competition Pattern", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Statistics as of September 5, if there is any omission, welcome to correct!
Just into September, more than 10 injections (in terms of drug name + group) have passed or are deemed to have passed the consistency evaluation
.
According to the data of the Intranet, the current evaluation/deemed overrated injections have exceeded 1,000 (in terms of drug names + groups), involving 264 varieties
.
From the perspective of evaluated enterprises, the top 10 enterprises have rated 17 or more injections, and the head enterprises such as Yangtze River, Kelun and Qilu have performed well; From the perspective of evaluated varieties, 7 of the TOP10 varieties have a peak sales of more than 2 billion yuan in the terminals of public medical institutions in China, of which 6 have 20 or more rated enterprises; From the perspective of treatment categories, the injectables have been evaluated to focus on the five hundred billion markets
.
.
According to the data of the Intranet, the current evaluation/deemed overrated injections have exceeded 1,000 (in terms of drug names + groups), involving 264 varieties
.
From the perspective of evaluated enterprises, the top 10 enterprises have rated 17 or more injections, and the head enterprises such as Yangtze River, Kelun and Qilu have performed well; From the perspective of evaluated varieties, 7 of the TOP10 varieties have a peak sales of more than 2 billion yuan in the terminals of public medical institutions in China, of which 6 have 20 or more rated enterprises; From the perspective of treatment categories, the injectables have been evaluated to focus on the five hundred billion markets
.
Injections have been rated as TOP10 enterprises: Yangzijiang, Kelun, Qilu performance is eye-catching
Injections have been rated as TOP10 enterprises: Yangzijiang, Kelun, Qilu performance is eye-catching More than 20 pharmaceutical companies have rated the number of injectable varieties of 10 or more, among the TOP10 enterprises, Yangzijiang ranked first with 50 evaluated varieties (12 as the first), Kelun Pharmaceutical ranked third with 43 overrated varieties (21 as the first), and Qilu Pharmaceutical ranked third
with 39 evaluated varieties (15 as the first).
with 39 evaluated varieties (15 as the first).
In addition, the number of rated varieties of China Biopharmaceuticals and Beite Pharmaceuticals has reached 30 or more, and the number of rated varieties of Hengrui Pharmaceutical, CSPC Pharmaceutical Group and Fu'an Pharmaceutical has reached 20 or more
.
Medicine.
Top 10 Injectables Rated (Group)
Source: MED2.
0 China Drug Review Database
0 China Drug Review Database
Yangzijiang Pharmaceutical's 50 overrated injections cover 11 therapeutic categories, focusing on systemic anti-infective drugs (10 varieties), nervous system drugs (8 varieties), anti-tumor and immunomodulators (8 varieties), musculoskeletal system (7 varieties) and other therapeutic fields; The first of the 12 injections / exclusive reviews, of which Sulgen Glucose Sodium Injection, Tedezolid Phosphate for Injection, etc.
are the first imitation (containing the first imitation of the dosage form).
are the first imitation (containing the first imitation of the dosage form).
Yangtze River Pharmaceutical has evaluated the injection
Note: With * for the first / exclusive review
Source: MED2.
0 China Drug Review Database
0 China Drug Review Database
The 43 overrated injections of Kelun Pharmaceuticals cover 8 therapeutic categories, focusing on the two therapeutic areas of hematological and hematopoietic system drugs (17 varieties) and systemic anti-infective drugs (11 varieties); The first of 21 injections / exclusive reviews, a number of enteral nutrition products won the first imitation (containing dosage form first imitation).
Kelun Pharmaceuticals has evaluated injections
Note: With * for the first / exclusive review
Source: MED2.
0 China Drug Review Database
0 China Drug Review Database
Qilu Pharmaceutical's 39 overrated injections cover 7 treatment categories, focusing on two major therapeutic fields: anti-tumor and immunomodulators (12 varieties) and systemic anti-infective drugs (12 varieties); The first of the 15 injections has been evaluated, of which aprepitant injection is the first imitation (containing the first imitation of the dosage form).
Qilu Pharmaceutical has evaluated the injection
Note: With * for the first / exclusive review
Source: MED2.
0 China Drug Review Database
0 China Drug Review Database
The number of rated enterprises TOP10 injections: siege of large varieties, 6 major varieties of hot
The number of rated enterprises TOP10 injections: siege of large varieties, 6 major varieties of hot More than 20 injections have been evaluated by 10 or more companies, among the TOP10 injections, the number of ambroxol hydrochloride injections has reached 40, the number of parecoxib sodium for injection has exceeded 30, and the number of omeprazole sodium for injection, pantoprazole sodium for injection, ceftriaxone sodium for injection, and espalprazole sodium for injection have reached 20 or more
.
Enterprise enterprise.
From the terminal sales of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions), the peak sales of omeprazole sodium for injection, pantoprazole sodium for injection, and ceftazidime for injection have exceeded 5 billion yuan
.
Hospital Hospital.
The number of rated enterprises TOP10 injections
Source: Intranet Database
Judging from the situation of collection and procurement, the number of injections that have been evaluated by 10 or more enterprises has been included in the national collection, and the sales scale of most injections has declined to varying degrees after being included in the collection, but there are also individual exceptions
.
.
Dexmedetomidine hydrochloride injection is 4 + 7 and expand the collection of varieties, Yangtze River with the advantage of exclusive evaluation, with a low reduction in the exclusive selection, after the selection of rapid release, driving the entire market rapid expansion; The concentrated solution for levetiracetam injection was included in the third batch of collection, and the volume of "barefoot" selected enterprises such as Hainan Puli Pharmaceutical, Hebei Renhe Yikang Pharmaceutical, chongqing Shenghuaxi Pharmaceutical co.
, Ltd.
drove the sales of the entire variety to increase
year by year.
, Ltd.
drove the sales of the entire variety to increase
year by year.
In recent years, the terminal sales of some collection injections in Public Medical Institutions in China (: 10,000 yuan)
Source: Intranet China's public medical institution terminal competition pattern
Overrated injection treatment category TOP10: focus on 5 hundred billion markets
Overrated injection treatment category TOP10: focus on 5 hundred billion markets More than 1,000 overrated injections (in terms of drug name + group) cover 11 treatment categories, and the proportion of five major therapeutic areas of systemic anti-infective drugs, digestive and metabolic drugs, nervous system drugs, blood and hematopoietic system drugs, anti-tumor and immunomodulators accounts for more than 10%.
Drugs drugs tumor tumors Overrated injection treatment category TOP10
According to data from the Intranet, the sales scale of the five treatment categories of systemic anti-infective drugs, digestive and metabolic drugs, nervous system drugs, blood and hematopoietic system drugs, anti-tumor and immunomodulators will exceed 100 billion yuan
in the terminals of China's public medical institutions in 2021.
in the terminals of China's public medical institutions in 2021.
In recent years, the proportion of injection sales in the terminal part of China's public medical institutions has been the proportion of injections
Source: Intranet China's public medical institution terminal competition pattern
From the distribution of dosage forms in the above 5 treatment categories, injections occupy a dominant position, of which injections account for more than 80% of drugs in the blood and hematopoietic system, which are mainly driven by the sales of human blood albumin, sodium chloride injection, glucose injection and other products; In addition, even under the influence of policies such as limiting the amount of import and limiting antibody, the proportion of injections in systemic anti-infective drugs is still increasing year by year, and it has approached 80%
in 2021.
in 2021.
Source: Intranet database, the official website of the State Food and Drug Administration, etc.
Note: Minenet "China's Public Medical Institutions Terminal Competition Pattern", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Statistics as of September 5, if there is any omission, welcome to correct!
Note: Minenet "China's Public Medical Institutions Terminal Competition Pattern", the statistical scope is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics, village clinics; The above sales are calculated
based on the average retail price of the product at the terminal.
Statistics as of September 5, if there is any omission, welcome to correct!
